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Abstract: COPD is a complex, heterogeneous condition. Even in the early clinical stages, 
COPD carries a significant burden, with breathlessness frequently leading to a reduction in 
exercise capacity and changes that correlate with long-term patient outcomes and mortality. 
Implementation of an effective management strategy is required to reduce symptoms, preserve 
lung function, quality of life, and exercise capacity, and prevent exacerbations. However, 
current clinical practice frequently differs from published guidelines on the management 
of COPD. This review focuses on the current scientific evidence and expert opinion on the 
management of moderate COPD: the symptoms arising from moderate airflow obstruction 
and the burden these symptoms impose, how physical activity can improve disease outcomes, 
the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of 
inhaled corticosteroids in this disease. We emphasize the importance of maximizing bron-
chodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related 
outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined 
patient groups.
Keywords: dual bronchodilation, inhaled corticosteroid, LAMA, LABA, tiotropium, 
anticholinergic
Introduction
COPD is a progressive lung disease characterized by airflow obstruction that results 
in breathlessness and disability.1 COPD carries a significant burden for patients and 
health-care systems alike,2–4 and rates are reported to be increasing.5 In fact, COPD 
is now the third-leading cause of death worldwide.6 In a population-based world-
wide study (BOLD initiative), the prevalence of COPD (GOLD stage 2 or higher) 
identified by postbronchodilator spirometry and questionnaires among individuals 
of age $40 years was 10.1%.7 Although a certain proportion of COPD cases remain 
undiagnosed and the recorded prevalence rates vary among countries, approximately 
15%–17% of current smokers and as many as 4%–12% of non- or ex-smokers develop 
COPD.8,9 COPD limits daily activities, affecting work and family life.10,11 A substan-
tial proportion of patients with mild–moderate COPD (GOLD stage 1 and 2) report 
poor health,12 impaired health-related quality of life (HRQoL),5 and exercise limita-
tion, often associated with dynamic hyperinflation during daily activities.13,14 Indeed, 
according to a recent report by O’Donnell et al, patients with COPD stage 1 and 2 
have both impaired exercise capacity and increased breathlessness at isotonic exercise 
when compared with age- and sex-matched controls.13 Impairment in exercise toler-
ance may in turn promote a sedentary lifestyle in patients with COPD, with inactivity 
levels rising dramatically over the course of the disease.15,16 Furthermore, more than 
a third of patients with mild airflow limitation develop COPD exacerbations,17 with 
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a subsequently heightened risk of future exacerbations.18 
Importantly, half of the patients with mild exacerbations of 
COPD do not report them as such at clinical visits, although 
exacerbations have been demonstrated to influence QoL and 
daily activities.19 Importantly, even mild–moderate COPD, 
especially when presenting with symptoms of chronic bron-
chitis, has been associated with increased mortality.20,21
This article summarizes the current scientific evidence 
and expert opinion on key topics related to the pharmacologi-
cal treatment of moderate COPD. These include the symptom 
burden associated with moderate airflow obstruction, the 
relevance of physical activity on disease outcomes, the value 
of long-acting dual bronchodilation, and the role of inhaled 
corticosteroids (ICSs) in COPD. For this purpose, experts 
from the COPD Platform, a collaboration among physicians 
from eleven Central and Eastern European countries, aimed 
at further understanding COPD and conducting clinical 
research in the region,22 discussed the mentioned topics dur-
ing a roundtable discussion in April 2016, and together with 
invited experts subsequently analyzed the scientific evidence 
via multiple exchanges over email.
Risk factors and lung-function 
decline in COPD
Smoking is a widely acknowledged risk factor for COPD. 
According to a recent Finnish study, 11.4% and 22.8% of 
a cohort of heavy smokers had developed COPD by 3 and 
6 years of follow-up, respectively.23 Developing COPD, how-
ever, does not solely depend on smoking exposure. Lange et 
al showed that 26% of people under the age of 40 years who 
had low baseline forced expiratory volume in 1 second (FEV
1
; 
,80% predicted) had developed COPD within 22 years of 
observation compared with 7% of those with baseline FEV
1
 
.80%.24 These findings suggest that early-life risk factors may 
contribute to COPD beyond the effects of smoking. In fact, in 
a European study conducted over 9 years, patients aged 20–45 
years with one or more childhood disadvantage factors (mater-
nal asthma, paternal asthma, childhood asthma, maternal smok-
ing, or childhood respiratory infections) showed significantly 
lower FEV
1
 levels than other patients of the same age. The 
degree of FEV
1
 decrease correlated with the number of risk 
factors present, as did the presence of COPD at study close.25 
Awareness of such risk factors may lead to earlier interventions 
and potentially to a reduction in the delays seen in achieving a 
diagnosis of COPD. The absence of spirometry data in clinical 
practice is a major contributor to delays in patient diagnosis.26,27 
This may result in unobserved disease progression and sub-
sequent clinical presentation of more advanced disease.28–30 
Indeed, in a subset of 366 patients with COPD identified from 
a US patient database, 50% suffered from moderate disease 
(GOLD 2) at the time of diagnosis, while 31% already had 
GOLD 3 (severe) or GOLD 4 (very severe) COPD.31
Such delays in diagnosing COPD may have several impli-
cations. In a large multicenter study, Dransfield et al observed 
lung-function decline over 5 years at a greater rate in patients 
with mild–moderate (GOLD 2) COPD than in those with more 
severe disease.32 According to another study, the fastest decline 
in FEV
1
 occurs during even mild (GOLD 1) COPD.33 The 
decline in lung function was increased further in patients who 
had already suffered a severe exacerbation at the time of the 
first visit (Figure 1).32 Therefore, preserving lung function early 
in the course of the disease may be considered an important 
goal of therapy to reduce morbidity and mortality.34–36
From a therapeutic point of view, it is needless to say that 
smoking cessation at any stage of the disease can prevent 
clinically significant airway obstruction and slow down the 
rate of decline in lung function,37 thus benefiting long-term 
outcomes.38 This effect is independent of sex, age, or baseline 
lung function, indicating that it is never too late to derive 
benefit from smoking cessation.
Rationale for maximizing 
bronchodilation in patients with 
moderate COPD
Long-acting muscarinic antagonists (LAMAs) selectively 
block receptor binding to reduce the bronchoconstrictive 
effects of acetylcholine on smooth-muscle cells in the 
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Figure 1 estimated changes in Fev1 by GOLD group and severe-exacerbation 
status.
Notes: The plot demonstrates that for each GOLD classification, those individuals 
with at least one severe exacerbation (dotted lines) had faster declines in Fev1 
on average compared with those who did not (solid lines). GOLD 0, no airway 
obstruction; GOLD 1, mild; GOLD 2, moderate; GOLD 3, severe; GOLD 4, very 
severe. Reprinted with permission of the American Thoracic Society. Copyright © 
2017 American Thoracic Society. Dransfield MT, Kunisaki KM, Strand MJ, et al. 2017 
Acute exacerbations and lung function loss in smokers with and without COPD. Am 
J Respir Crit Care Med. 2017;195:324–330.32 The American Journal of Respiratory and 
Critical Care Medicine is an official journal of the American Thoracic Society.
Abbreviation: PRISm, preserved ratio-impaired spirometry.
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lungs.39 Long-acting β
2
-adrenoceptor agonists (LABAs) 
further promote a bronchodilation effect through smooth-
muscle relaxation via the β
2
-adrenergic receptors40 and 
through inhibition of acetylcholine release.41 On the other 
hand, anticholinergics interfere with PKC inhibition of the 
downstream signaling of the β
2
-adrenergic receptor.42 It is 
worth noting that with LAMAs acting predominantly within 
the proximal sections of the lung and LABAs typically within 
the distal sections, they provide a complementary effect on 
lung function.39,43
Treating patients with moderate COPD using broncho-
dilators may help to preserve and protect lung function,44 
increase exercise capacity,45 reduce exacerbation rates,44,46 
and reduce symptoms, resulting in better health status, lower 
disease burden, and improvements in overall QoL.47,48 In 
fact, a recent study of inhaled tiotropium in patients with 
early-stage chronic COPD (GOLD stage 1 or 2) indicated 
that the annual decline in FEV
1
 measured after bronchodila-
tor use was significantly less in the tiotropium group than 
the placebo group (29±5 mL per year vs 51±6 mL per year, 
P=0.006), indicating a potentially disease-modifying effect 
of long-acting anticholinergic therapy when established 
early in the disease course.49 Whether these benefits extend 
to the level of a survival benefit remains to be established. 
Post hoc analyses of both the TORCH and UPLIFT studies 
suggested a survival benefit of sustained bronchodilation in 
moderate-severe COPD; however, these findings have not 
been formally proven in prospective studies.36,50
There is emerging scientific evidence for the use of fixed-
dose combinations of LAMAs and LABAs with the intention 
of achieving maximal and sustained bronchodilation with 
subsequent clinical benefits. In this context, we discuss results 
from recent randomized controlled trials (RCTs) investigat-
ing the effects of dual bronchodilation on various clinical 
outcome measures in patients with COPD.48,51–54
Preserving and protecting lung 
function via pharmacological 
treatment
Recent studies have demonstrated the superiority of LAMA-
LABA combinations compared with LAMA or LABA mono-
therapy with respect to lung function, symptoms, and QoL in 
the first-line setting of patients with moderate COPD.50,55–58 
In a double-blind, placebo-controlled, multicenter, Phase III, 
incomplete crossover study by Beeh et al that enrolled 
259 patients, a fixed-dose combination of tiotropium and 
olodaterol significantly improved lung function versus its 
individual components, with a 6-week improvement in 
FEV
1
 area under the curve to 24 hours (AUC
0–24
) of 244 mL 
compared with 117 mL and 129 mL for tiotropium and 
olodaterol alone, respectively.58
In a post hoc analysis of 5,162 patients enrolled in the 
combined TONADO 1 and 2 Phase III trials, Ferguson et al 
demonstrated comparable improvements in FEV
1
 AUC
0–3
 
with dual bronchodilation with tiotropium and olodaterol 
versus the monocomponents in both treatment-naïve and 
pretreated patients.57 Interestingly, improvements in lung 
function from baseline were generally greater in patients 
with GOLD stage 2 COPD than those with GOLD stage 3–4 
COPD.55 Furthermore, it has been shown using the fixed-dose 
combination of tiotropium and olodaterol that the LAMA and 
LABA components of dual bronchodilation have an additive 
effect on lung function, resulting in improved functional 
residual capacity, residual volume, breathlessness, and QoL 
compared with either component as monotherapy.38,55,56,58,59 
Statistically significant improvements in hyperinflation 
expressed as a reduction of functional residual capacity 
from baseline at 2.5 hours postdose were also observed, 
with -435 mL and -431 mL for olodaterol and tiotropium 
monotherapy, respectively, compared with -547 mL for the 
combination therapy.56
Clinically meaningful improvements in HRQoL have 
been recorded with the fixed-dose combination of tiotro-
pium and olodaterol, showing improvements in St George’s 
Respiratory Questionnaire (SGRQ) total score after 12 weeks 
by 4.89 versus placebo and 2.49 versus tiotropium alone.55 
Importantly, the incidence of adverse events is comparable 
between the fixed-dose combination and tiotropium or 
olodaterol monotherapy.38,55,56 When considering these results, 
it should be noted that the patient populations in these studies 
varied, with the inclusion of high proportions of patients 
with moderate COPD (GOLD stage 2)51 or comorbidities,60 
as well as pretreated38,56 and treatment-naïve patients.38,61
Other dual-action bronchodilator combinations have shown 
similar benefits. Donohue et al conducted a 24-week study of 
umeclidinium (UMEC)–vilanterol (VI) against the individual 
components or placebo, finding that all active treatments 
produced statistically significant improvements in trough 
FEV
1
 compared with placebo on day 169 (0.072–0.167 L, 
all P,0.001), that the increase in trough FEV
1
 with UMEC 
(62.5)–VI (25 µg) was significantly greater than with mono-
therapies (0.052–0.095 L, P#0.004), and that statistically 
significant HRQoL improvements were seen in SGRQ scores 
compared with placebo.62 In the SHINE study, an indacaterol 
and glycopyrronium combination was assessed against the 
individual components in patients with moderate–severe 
COPD. Trough FEV
1
 was statistically higher in the combina-
tion arm than the single agents (P,0.001).63 SGRQ scores in 
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this study at week 12 were statistically higher for the combina-
tion than placebo (P,0.001) and glycopyrronium (P=0.02), 
but this finding was not seen against indacaterol or with any 
single agent vs placebo. Overall, there is increasing evidence 
for a beneficial effect of dual bronchodilation in patients with 
COPD compared with single agents.
Bronchodilators and exercise 
limitation
Patients in the early stages of COPD suffer from noticeable 
breathlessness on exertion, predominantly owing to dynamic 
hyperinflation,13,64 and this phenomenon is present even 
during daily activities.14 In turn, dyspnea during exercise is 
likely to contribute to the significant drop in activity levels 
seen in patients with mild–moderate COPD.15 A controlled 
multicenter study by Troosters et al involving 70 patients 
with COPD and 30 healthy controls demonstrated a 29% 
reduction in the number of steps per day and a 59% reduc-
tion in the time spent on activities at moderate intensity in 
patients with GOLD stage 2 COPD compared with control 
individuals.65
Sedentary behavior and lack of physical activity are 
strong and independent predictors of all-cause mortality in 
COPD.66–69 Taking steps to maintain regular exercise thus 
has a positive impact on QoL and COPD progression,67 
preventing a downward spiral in physical function and con-
ditioning.70 Indeed, pulmonary rehabilitation (PR) is regarded 
as being one of the most effective nonpharmacological treat-
ments for people with COPD, leading to improvements in 
exercise tolerance, dyspnea, and HRQoL.71,72 Importantly, 
some of these benefits may be achieved by improvements 
in accessible alveolar lung volume, whereas patients with 
severe diffusion-capacity impairment and presence of 
ventilation inhomogeneity appear to experience smaller 
improvements in exercise tolerance.73 By the addition of a 
long-acting anticholinergic bronchodilator to PR, clinically 
meaningful improvements in dyspnea and health status 
have been seen over PR alone.74 Studies on the effect of 
dual bronchodilation in association with PR in patients with 
COPD are still lacking.
It may be suggested that improving lung function and 
reducing elevated lung volume by sustained bronchodilation 
can reduce dynamic hyperinflation in COPD and thus contrib-
ute to patients’ improved exercise tolerance. The introduction 
of dual-bronchodilator treatments into real-life clinical prac-
tice may further facilitate increased exercise capacity.75,76 In 
a 12-week, double-blind, placebo-controlled study involving 
404 patients, combined tiotropium and olodaterol provided 
a 21% improvement in endurance shuttle walking versus 
placebo.75 Similarly, a double-blind, double-dummy, three-
period crossover study of 85 patients revealed that combined 
glycopyrronium and indacaterol significantly improved 
patients’ exercise endurance time compared with placebo.76 
Once published, the recently completed PHYSACTO77 
study should provide additional clarity on the physical 
activity benefits of dual bronchodilation. This randomized, 
partially double-blinded, placebo-controlled, parallel-group 
trial involving patients from 34 multinational sites looks at 
multicomponent interventions (tiotropium, tiotropium + 
olodaterol, or tiotropium + olodaterol + exercise training) 
that are designed to support behavior change related to 
physical activity.77 Recently, the MORACTO 1 and 2 studies 
assessed the effects of tiotropium–olodaterol on inspira-
tory capacity and exercise-endurance time in patients with 
moderate–severe COPD. Tiotropium (2.5/5 µg)–olodaterol 
(5/5 µg) provided significant improvements in inspiratory 
capacity versus placebo and monotherapies (P,0.0001) and 
significant improvements in exercise-endurance time versus 
placebo (P,0.0001).78 It would be of interest to perform 
a prospective study to assess PR by directly comparing a 
LAMA-LABA combination plus PR to the LAMA-LABA 
combination alone.
However, a number of questions remain unanswered in 
this context. Will the patients with COPD actually improve 
their activity levels in a real-life setting after the initiation 
of optimal bronchodilator treatment? Is there a threshold of 
irreversibility with regard to physical deconditioning based 
on biological grounds, such as systemic inflammation? And 
what is the role of such comorbidities as heart failure in 
exercise-capacity limitations?
The effect of bronchodilators on 
exacerbation rates in COPD
An important consideration in the treatment of COPD is the 
prevention of exacerbations. Although ICSs have been tradi-
tionally viewed as the main treatment for patients at risk of 
exacerbations (especially for postbronchodilator FEV
1
 #50% 
predicted value), there is accumulating evidence to suggest 
an important role for bronchodilators in the prevention of 
exacerbations.79–82 In a previous clinical trial conducted in 
37 countries, 5,993 patients were randomized to receive 
4 years of treatment with either 18 µg once-daily tiotropium or 
placebo delivered by matching inhalation devices. The results 
showed that tiotropium significantly reduced exacerbation 
rates versus placebo in largely pretreated (with medicines 
other than LAMAs) patients with GOLD stage 2 COPD.46 
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Vogelmeier et al subsequently demonstrated superiority 
of LAMAs over LABAs in reducing exacerbation rates 
in COPD, suggesting the presence of various mechanisms 
and pathways that anticholinergic and β
2
-sympathomimetic 
agents affect, leading to fewer exacerbations.83 A similar 
signal was observed in patients with severe COPD when 
using a LABA with 24-hour efficacy.84 Combining LAMA 
and LABA agents, however, may exert additive effects 
that could further reduce the number of exacerbations in 
COPD. Indeed, combination of sustained bronchodilation 
with subsequent lung-volume reduction might contribute to 
patent airways, thus protecting patients from fluctuations in 
the severity of airflow obstruction that potentially lead to an 
exacerbation.50,85 A recent study investigating the effects of 
tiotropium and indacaterol on stable patients with moderate–
severe COPD showed that the vital capacity in these patients 
had increased at 1 hour postadministration, but not the 
transpulmonary pressure curve, indicating that it is possible 
to achieve a positive effect on gas exchange without risking 
small-airway damage.86
Furthermore, in addition to having low-level anti-
inflammatory effects, both LAMAs and LABAs have dem-
onstrated reductions in mucus production and improvements 
in mucus clearance, which in turn may reduce exacerbation 
risk by a robust increase in the threshold of sensitivity to 
exacerbation-precipitating triggers.87–89 Finally, bronchodila-
tors have been demonstrated to reduce both cardiac preload 
and afterload, thus improving cardiac function.90 Given that 
left heart failure is considered an important trigger of COPD 
exacerbations,91 improvements in cardiovascular morbidity 
associated with long-term maintenance-bronchodilator treat-
ment may contribute to the stability of COPD.92,93
As expected, a combination of two bronchodilators may 
significantly improve lung function compared with the com-
bination of a single bronchodilator (usually a LABA) with 
an ICS. Indeed, Rabe et al demonstrated superiority of a free 
combination of tiotropium and formoterol over a fixed-dose 
combination of salmeterol and fluticasone for FEV
1
 AUC.94 
These findings were further strengthened by the introduction 
of fixed-dose combination dual-bronchodilator therapy. After 
6 weeks of once-daily dual bronchodilation with tiotropium 
(5/5 µg) and olodaterol (2.5/5 µg) compared with twice-
daily salmeterol (50/500 µg) and fluticasone propionate 
(50/250 µg), statistically significant improvements were seen 
in FEV
1
 AUC
0–12
 (P,0.0001 for all comparisons).50 The 
combination of tiotropium and olodaterol was also superior 
to the combination of salmeterol and fluticasone propionate 
for improving secondary lung-function end points, including 
FEV
1
 AUC
0–24
 (P,0.0001 for all comparisons). A fixed-dose 
combination of indacaterol and glycopyrronium similarly 
offered a significant and clinically meaningful improvement 
in FEV
1
 AUC
0–12
 at week 26 compared with that achieved 
with a combination of salmeterol and fluticasone.95 Similar 
findings with respect to lung-function improvements over 
LABA-ICS combinations have been observed with other 
dual-bronchodilator combinations, such as umeclidinium–
vilanterol96 and aclidinium–formoterol.93,97
A previous post hoc analysis from a clinical trial of 
LAMA-LABA versus LABA-ICS combinations demon-
strated lower exacerbation rates with the dual-bronchodilator 
combination, indicating that the aforementioned pleiotropic 
effects of dual bronchodilation may be more potent than the 
anti-inflammatory effects of ICSs on the course of COPD. 
More recently, results from a prospective RCT (FLAME) 
confirmed superiority of LAMA-LABA over LABA-ICS 
combinations in reducing exacerbation rates in patients 
with COPD at risk of exacerbations.52 This study was a 
year-long RCT designed to compare the annual number 
of COPD exacerbations as the primary end point between 
LAMA-LABA (indacaterol–glycopyrronium once daily) 
and LABA-ICS (salmeterol–fluticasone twice daily) study 
groups. The LAMA-LABA combination not only showed 
noninferiority but also superiority over the LABA-ICS 
combination with an 11% lower annual rate of COPD exac-
erbations plus a 16% lower risk of exacerbation reflected in a 
longer time to first exacerbation in the LAMA-LABA group 
versus the LABA-ICS group.52 However, it should be noted 
that “noninferiority only” was demonstrated for the 20% of 
patients with COPD in the study who had a history of two or 
more exacerbations. This is of specific importance, as in the 
recent GOLD guidelines,98 patients are stratified into different 
risk groups with respective treatment recommendations based 
on symptom load and exacerbation history, but not on FEV
1
. 
Indeed, a recent analysis from a cohort of 3,500 patients with 
stable COPD in Central and Eastern Europe99 showed that 
35% of patients in group D according to the previous version 
of the GOLD guidelines100 would move to group B according 
to the GOLD 2017 revision, because of a lack of real exac-
erbations.101 Of note, the majority of these patients (71%) 
were on ICS treatment, and according to GOLD 2017 should 
not receive ICSs any longer. It remains to be determined 
whether and to what extent the guideline recommendations 
on the use of ICS-containing regimens will be translated into 
real-life prescription behavior.98 Furthermore, these studies 
were undertaken using LABA-ICS combinations, so until the 
results of ongoing research to address the effect and role of 
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adding ICSs to LAMA-LABA combinations are available,102 
the wider spectrum of the usefulness of ICSs in the treatment 
pathway cannot be fully elucidated.
In addition to improvements in patient outcomes, dual 
bronchodilation also seems to reduce demand for health-care 
resources, with LAMA-LABA patients requiring signifi-
cantly less rescue medication than patients receiving LAMA 
or LABA alone.103,104 Whether dual bronchodilation will dem-
onstrate superiority over treatment with single bronchodila-
tors for moderate–severe exacerbation rates will be assessed 
in the Phase III DYNAGITO trial, which is a prospective 
RCT investigating a tiotropium-containing LAMA-LABA 
combination versus bronchodilator monotherapy.105
On the basis of the accumulating evidence for dual 
bronchodilators with respect to lung function, symptoms, 
HRQoL, and exacerbation rates, first-line treatment with 
LAMA-LABA fixed-dose combinations may be considered 
in the majority of treatment-naïve patients with symptomatic 
COPD. In contrast, the role of ICS-containing drug regimens 
in COPD needs further personalized evaluation.98,106
The role of ICSs in COPD
ICS monotherapy in COPD
The paradigm of beneficial effect of ICSs in asthma and 
the similarity of airway symptoms in the two diseases have 
led to the use of ICSs being extended to COPD. However, 
unlike asthma, steroid resistant inflammation occurs in most 
patients with COPD, explaining the ineffectiveness of ICSs 
in this disease.107 Early trials of ICSs in COPD conducted 
prior to the availability of long-acting bronchodilators 
showed symptomatic benefit without affecting FEV
1
 decline 
or mortality.108–110 The main beneficial effect of ICSs in 
COPD, a modest decrease in moderate–severe exacerba-
tions was largely limited to patients with severe airflow 
limitation.111 Critical appraisal revealed important method-
ological issues that underlay a significant overestimate of 
this salutary effect.112
ICS-LABA in COPD
When ICS-LABA combination inhalers became available, 
the problem of “copy-pasting” ICS-based asthma therapies 
onto COPD recurred. The TORCH RCT investigated the 
effects of an ICS-LABA combination on mortality and key 
secondary outcomes in severe COPD.50 This trial, notable 
for complete follow-up (intention-to-treat) for survival, is 
often perceived as “almost achieving” a statistically signifi-
cant survival benefit. However, post hoc factorial analysis 
found a statistically significant 19% survival advantage to the 
LABA component (salmeterol), but not to the ICS component 
(fluticasone).113 Interpretation of the TORCH results pertain-
ing to benefits in exacerbations and decline in FEV
1
 and QoL 
is prone to bias of differential dropout, owing to incomplete 
follow-up for these secondary end points.114
ICS use as per GOLD reports
Since 2011, in acknowledgment of the aforementioned 
observations and the demonstrated superiority of long-acting 
bronchodilators over ICSs in improving lung function and 
exercise capacity,115 GOLD COPD recommendations against 
ICS monotherapy limited ICS use in COPD to ICS-LABA 
combinations only. This further emphasizes the dominant 
contribution of the long-acting bronchodilator (in this 
case, LABA) component of ICS-LABA combinations in 
COPD and in contrast to the dominant role of ICSs versus 
bronchodilators in asthma. Given the increasing evidence 
for the effectiveness of dual long-acting bronchodilation in 
improving key COPD-outcome measures, the updated GOLD 
2017 report recommends that ICS-containing drug regimens 
be restricted to patients with severe airflow limitation and 
frequent exacerbations despite maximized bronchodilator 
treatment.98
The challenge of implementing guidelines
As many as two-thirds or more of primary care physicians116 
and a third of respiratory specialists do not follow the GOLD 
recommendations in clinical practice.117 Using a large 
primary-care database from the UK, Brusselle et al recently 
demonstrated that 25% of patients receive ICS-containing 
treatment within the first year of treatment initiation, with 
almost 100% receiving triple-inhaler therapy within 8 years 
of diagnosis.118 Similarly, both Price et al and Barrecheguren 
et al reported that a high proportion of patients with mild–
moderate COPD were receiving ICS-based treatment in 
clinical practice.119,120 Several factors contribute to the 
discrepancy between guidelines and real-life practice. The 
long-standing underutilization of spirometry and unfamiliar-
ity with its use in primary care,121–125 together with erroneous 
beliefs regarding the benefits of ICSs in COPD and overused 
asthma–COPD overlap in diagnostic labeling, all contribute 
to difficulties in differentiating COPD from asthma.124–126 
The complexity of the GOLD classification of COPD and 
the ever-increasing multiplicity of inhaler options may add 
difficulties in proper implementation of the guidelines.98 
Habitual prescribing patterns and existing prescriptions from 
a prior health-care professional may contribute to delays 
in the clinical implementation of recommendations from 
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updated guidelines.127 Inadequate symptom control and/or 
persistent breathlessness due to common comorbidities may 
prompt the addition of inhaled therapy. These factors may 
call for increased education and awareness, particularly for 
primary-care physicians and specialists, who frequently 
initiate treatment.
ICSs and pneumonia in COPD
In patients not fulfilling the aforementioned criteria, ICS 
use may have an unfavorable risk:benefit ratio.128 Prolonged 
ICS use in these patients has been associated with increased 
rates of pneumonia, tuberculosis, osteoporosis, cataracts, 
diabetes, and oropharyngeal candidiasis.129,130 Whether 
this increase is class-related or brand-related remains to be 
decided.131–133 Again, the TORCH trial drew attention to the 
adverse associations linking ICS use in COPD to the events 
of pneumonia.134 According to a recent meta-analysis, the 
estimated unadjusted risk of pneumonia associated with 
ICSs was increased in both randomized trials (RR 1.61) and 
in observational studies (OR 1.89), without evidence of an 
increase in case fatality.135 However, a greater number of 
patients with COPD receiving ICSs are hospitalized due to 
severe pneumonia than those not receiving ICSs; therefore, a 
possibility exists that more patients with COPD will die from 
pneumonia, even if the case-fatality rate is the same once 
hospitalized.136 The risk of pneumonia decreases, however, 
by 50% within 4 months of ICS discontinuation.137 It should 
be emphasized, however, that for patients in whom ICSs are 
correctly indicated (as detailed herein), their benefits could 
outweigh the increased risk of pneumonia.
Asthma and COPD overlap
In recognition of patients presenting with clinical features of 
both asthma and COPD, associated with an increased burden 
of symptoms and exacerbations,138,139 both GOLD and GINA 
jointly formulated a 2015 document recommending that 
these patients with asthma–COPD overlap should be treated 
with ICSs, irrespective of their lung-function impairment, to 
prevent asthma-related morbidity and mortality.100,140 The 
stated prevalence of this group of patients is 5%–45% of those 
with COPD, and accounted for 7% of patients with COPD 
in the Central and Eastern Europe POPE study.99 The 2017 
version of the GOLD report treats asthma–COPD overlap as 
an overlap phenomenon, rather than a distinct syndrome,98 
and the 2015 appendix developed by the GINA and GOLD 
committees addressed the difficulty of this clinical defini-
tion, suggesting several characteristic clinical features.141 
These include a history of asthma and other respiratory 
symptoms before the age of 40 years, airflow limitation not 
being fully reversible, a history of allergies, and the pres-
ence of eosinophils and/or neutrophils in the sputum. These 
patients have been largely excluded from both asthma and 
COPD trials, meaning that there is no documented evidence 
on the effective management of this group. Therefore, the 
presumed effectiveness of ICSs in patients with asthma–
COPD overlap remains to be established, especially as the 
underlying inflammatory endotype is often noneosinophilic 
and thus unresponsive to treatment with ICSs and probably 
also with anti-IL5.142–144
Peripheral blood eosinophil count 
in COPD
Evidence of eosinophilic inflammation using blood eosino-
philia as a surrogate marker may be a useful predictor of a 
beneficial response to ICS treatment in COPD, as higher 
effectiveness of ICS-containing regimens on lung function 
and exacerbations has been reported in patients with COPD 
who have higher peripheral blood eosinophil counts.145–148 
A reanalysis of the former ISOLDE study suggests that a 
baseline blood eosinophil count $2% identifies those patients 
with COPD who may benefit from ICS-containing regimens, 
leading to a reduction in the rate of decline in FEV
1
.149 
Some patients with COPD have predominantly eosinophilic 
inflammation and might respond to high doses of ICSs and 
newly developed antieosinophil therapies.144 Recent results 
indicated that patients with GOLD 3 or GOLD 4 COPD 
and eosinophil counts of more than 300 cells/µL (or 4%) 
were more likely to experience exacerbations following 
ICS withdrawal.148 In the GOLD 2017 revised guidelines, 
however, the current use of blood eosinophils to guide ICS 
treatment in COPD is not recommended, owing to the lack 
of prospective RCTs using circulating eosinophils to titrate 
and/or target the use of ICSs in treating the disease.98 Except 
where concomitant asthma is present, the inclusion of ICSs 
based on peripheral eosinophil count requires further valida-
tion before it can be generally recommended in therapeutic 
regimens for patients with COPD.
ICS withdrawal in COPD
Previous studies have indicated that abrupt withdrawal of 
ICSs increases the risk of exacerbations and results in some 
worsening of lung function.140,154 A recent review of RCTs 
involving ICS withdrawal, however, supports the withdrawal 
of ICSs in patients with moderate COPD at low risk of exac-
erbation who are receiving adequate background therapy 
with long-acting bronchodilators.155 The recent WISDOM 
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study demonstrated that apart from a mild 40 mL decrease in 
FEV
1
,156 there was no increase in exacerbation risk after ICS 
withdrawal in patients with severe COPD on triple-inhaler 
therapy.156 Importantly, the WISDOM study assessed the 
possibility of stepwise withdrawal of ICSs from patients 
with GOLD stage 3–4 COPD and a history of at least one 
exacerbation during the previous 12 months.156 Following 
6 weeks of treatment with tiotropium, salmeterol, and fluti-
casone, patients were randomized for ongoing treatment or 
stepwise reduction of ICSs.154 Over the 3-month withdrawal 
period, the HR for a first moderate or severe acute exacer-
bation was 1.06 (95% CI 0.94–1.19) with ICS withdrawal 
compared with continued treatment, thereby indicating non-
inferiority.156 A recent meta-analysis of the benefit of ICS 
withdrawal showed mixed results: although there was no sig-
nificant increase (P,0.05) in the rate of COPD exacerbation 
overall, there remained a clinically important increased risk 
of severe exacerbation (RR .1.2).157 Withdrawal was also 
significantly associated with decreased FEV
1
 and HRQoL 
(P,0.001), although not in a clinically important manner. 
The GOLD 2017 recommendations suggest considering ICS 
withdrawal in patients with continuing exacerbations despite 
triple-inhaler therapy (ICS failure).99
Although safe in selected patients,154,158 implementing 
ICS withdrawal in clinical practice requires both thoughtful 
patient management and comprehensive physician educa-
tion to identify suitable patients and handle the withdrawal 
process. This sort of decision may be sensitive, especially in 
cases where patients have been on ICS-containing therapies 
for a long time. Recently, an algorithm was proposed that 
provides physicians with a practical guide for the withdrawal 
of ICSs.160 Building on the GOLD recommendations, the 
GINA–GOLD consensus statement on the asthma–COPD 
overlap phenotype, and the WISDOM trial, the algorithm 
provides a stepwise approach to identifying appropriate 
patients and managing ICS withdrawal.159
Consistent with this stepwise recommendation and a 
recent proposal of phenotype-driven therapy,105 the follow-
ing was suggested:159
1. review and optimize current COPD management, ensur-
ing clinical stability and optimal long-acting bronchodila-
tor background therapy
2. evaluate the risk–benefit profile of continuing ICSs; in 
particular, identify whether the patient has asthma–COPD 
overlap and/or severe airflow limitation with evidence 
of eosinophilia and frequent exacerbations; if this is the 
case, continuation of ICSs is currently warranted
3. if the patient does not fulfill the criteria specified in point 
2, first ensure optimized bronchodilation with LAMA-
LABA treatment, then perform a stepwise withdrawal of 
ICSs, reducing the dose every 6–12 weeks
4. follow-up every 3 months for the first year.
Although further validation is required, this proposed 
algorithm159,160 represents an important first step in the safe 
and effective management of ICS withdrawal.
Conclusion
There is increasing clinical evidence for the effectiveness 
of fixed-dose combination dual-bronchodilator treatment in 
achieving improved patient-related outcomes and decreasing 
the burden of moderate COPD. Based on clinical improve-
ments, lung-function benefits, and reduced exacerbation 
rates, together with a favorable safety profile, LAMA-LABA 
combinations may be considered the first-line treatment for 
the majority of patients with moderate or severe COPD. 
Adding an ICS component should generally be reserved for 
targeted use in patients with frequent exacerbations despite 
dual bronchodilation with a fixed-dose combination and in 
patients with a history of and/or clinical signs of asthma. 
Stepwise ICS withdrawal should be considered in patients 
with COPD and low exacerbation risk and in those with 
repeated exacerbations despite triple-inhaler therapy.
The current availability of a plethora of inhalers for 
COPD management has both advantages and disadvantages. 
In particular, unfamiliarity with the different classes and 
functions of the agents, especially among general practitio-
ners, can lead to confusion of both patients and prescribing 
physicians. While there is an ongoing need for new classes 
of therapy, comprehensive patient care must also include 
appropriate education regarding adherence and inhaler tech-
nique, as well as nonpharmacological therapies, mainly PR, 
to ameliorate the frailty of patients with COPD.
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